Research - Development - Production

A national high-tech enterprise specializing in R&D and production of peptides and related derivatives.

about_bg

About us

Hangzhou Go Top Peptide Biotech Co., Ltd. was founded in 2014, is a national high-tech enterprise specializing in R&D and production of peptides and related derivatives. It is also a governing unit of Polypeptide Branch of China Biochemical and Pharmaceutical Industry Association. At present, the company has a peptide research and development center in Hangzhou, covering an area of more than 4,000 square meters, and two commercial peptide factories in Shangyu and Anji, Zhejiang, with several complete peptide production lines, several sets of large-scale peptide synthesis equipment, imported HPLC analysis and preparation equipment, and equipped with a GMP standard clean laboratory. The company has passed the ISO9001:2015 quality management system certification.

 

 

Our Products

Our News

  • Not just reducing blood sugar and weight! Somalutide ushers in a new era of multi disease treatment, clinical trials provide strong evidence

    Not just reducing blood sugar and weight! Somalutide ushers in a new era of multi disease treatment, clinical trials provide strong evidence

    When it comes to semaglutide, many people are familiar with its hypoglycemic and weight reducing eff...

  • Sanya Conference Record: GoTop Biotechnology delves deeper into the peptide field and discusses technological breakthroughs and industrial landing with industry university research partners

    Sanya Conference Record: GoTop Biotechnology delves deeper into the peptide field and discusses technological breakthroughs and industrial landing with industry university research partners

    The 11th National Peptide Drug R&D and Scale Production Frontier Technology Academic Exchange Confer...

  • Go Top Biotech Makes Its Debut at CPHI Frankfurt 2025, Connecting European Business Opportunities Through End-to-End Supply Chain Services

    Go Top Biotech Makes Its Debut at CPHI Frankfurt 2025, Connecting European Business Opportunities Through End-to-End Supply Chain Services

    From October 28 to 30, 2025, the 2025 World Pharmaceutical Ingredients Europe Exhibition (CPHI Frank...

  • Future Potential Oral GLP-1 Weight Loss Drug - Amycritin

    Future Potential Oral GLP-1 Weight Loss Drug - Amycritin

    Novo Nordisk's latest Phase II clinical data show that the single molecule GLP-1+amylin dual agonist...

Cooperation Partners

  • 清华大学
  • 复旦大学
  • 同济大学
  • 南开大学
  • 西湖大学
  • 浙江大学
  • 浙江中医药大学
  • 1
  • 3
  • 2